Protalix BioTherapeutics 8-K Report: Key Developments & Stock Insights

Based on the provided section of the financial report, here are the key pieces of information and insights extracted:

1. Entity Information:

• Company Name: Protalix BioTherapeutics, Inc.
• CIK (Central Index Key): 0001006281
• SEC File Number: 001-33357
• Tax Identification Number (EIN): 65-0643773

2. Address:

• Location: 2 University Plaza, Suite 100, Hackensack, NJ 07601
• Phone Number: 201-696-9345

3. Financial Instrument:

• Common Stock: The company has common stock with a par value of $0.001.

4. Trading Information:

• Ticker Symbol: PLX
• Exchange: NYSE American (NYSEAMER)

5. Filing Type:

• The report is associated with an 8-K filing, which indicates that the document is likely reporting significant events or changes that are important to shareholders.

6. Reporting Period:

• The report covers a specific date: December 27, 2024, indicating that it may contain information relevant to that day or events occurring on that date.

Insights:

• The 8-K filing signifies that there may have been important developments or announcements from Protalix BioTherapeutics on December 27, 2024, which could affect the company's stock performance or operational strategy.
• The common stock’s low par value ($0.001) suggests that it may be a growth-oriented company that could be reinvesting profits rather than paying out substantial dividends.
• The location and contact information indicate that the company is based in Hackensack, New Jersey, which may be relevant for stakeholders interested in regional business activities or potential partnerships.

Overall, this information would be crucial for investors, analysts, and stakeholders monitoring Protalix BioTherapeutics’ activities and financial health.